5-amino-1mq Peptide

Obesity has become a major global public health challenge. Its core pathological feature is excessive accumulation of adipose tissue, accompanied by abnormal proliferation, differentiation, and metabolic dysfunction of adipocytes, which in turn induce a series of complications including insulin resistance, non‑alcoholic fatty liver disease, and cardiovascular diseases. Traditional obesity intervention strategies (e.g., dietary control, exercise, conventional weight‑loss drugs) are often limited by slow onset, obvious side effects, and high rebound rates, and can hardly fundamentally reverse the abnormal metabolic phenotype of adipose tissue.

Abnormal adipocyte differentiation (adipogenesis) is one of the key causes of adipose tissue accumulation. Excessive differentiation of preadipocytes into mature adipocytes increases adipocyte number and size, ultimately leading to obesity. Studies have found that NNMT expression gradually rises during adipocyte differentiation, and its enhanced activity promotes the differentiation of preadipocytes into mature adipocytes by depleting NAD⁺ and inhibiting the SIRT1 longevity pathway. NNMTi can block this process by precisely inhibiting NNMT, thereby reducing the formation of mature adipocytes.

In in vitro cell experiments using 3T3‑L1 preadipocytes as a model, treatment with NNMTi significantly reduced preadipocyte differentiation efficiency and markedly downregulated the expression of adipocyte markers (such as PPARγ and C/EBPα) in a dose‑dependent manner. At a concentration of 30 μM, it inhibited more than 70% of adipogenesis and significantly reduced intracellular triglyceride accumulation. Further mechanistic studies showed that NNMTi increases intracellular NAD⁺ levels and activates the SIRT1 pathway by inhibiting NNMT, thereby suppressing the transcription of adipogenic genes and preventing the maturation of preadipocytes.This research provides a new perspective for understanding the molecular mechanism of adipocyte differentiation, confirms the key role of NNMTi in regulating adipogenesis, and lays a foundation for subsequent obesity intervention studies.

In obesity, the metabolic balance of adipose tissue is disrupted, characterized by enhanced lipogenesis and weakened lipolysis, leading to continuous fat accumulation. By inhibiting NNMT, 5‑Amino‑1MQ Peptide reshapes the metabolic phenotype of adipose tissue, promotes lipolysis, increases energy expenditure, and restores dynamic balance of fat metabolism - one of its core weight‑loss mechanisms.

In vivo animal experiments showed that daily administration of NNMTi for 28 days to diet‑induced obese (DIO) mice significantly upregulated the expression of lipolysis‑related genes (such as ATGL and HSL) and downregulated lipogenesis‑related genes (such as FAS and ACC), indicating that NNMTi effectively promotes fat breakdown and inhibits fat synthesis. Meanwhile, NNMTi treatment significantly increased energy expenditure in mice, an effect closely related to elevated NAD⁺ levels following NNMT inhibition.

As a key coenzyme in mitochondrial energy metabolism, increased NAD⁺ enhances mitochondrial oxidative phosphorylation, promotes triglyceride breakdown in adipocytes, and converts fat into energy for the body, thereby reducing adipose tissue accumulation. Notably, unlike conventional weight‑loss drugs, it promotes lipolysis without affecting normal appetite. No significant difference in food intake was observed between treated and control mice in related studies, indicating that its anti‑obesity effect mainly depends on regulating fat metabolism rather than suppressing appetite - a unique advantage in obesity research.

In obesity, adipose tissue develops chronic low‑grade inflammation with abundant release of pro‑inflammatory factors (such as TNF‑α and IL‑6), disrupting the adipose microenvironment, further worsening fat metabolic abnormalities and insulin resistance, and forming a vicious cycle. Studies have found that high NNMT expression promotes the release of inflammatory factors in adipose tissue, and NNMTi can effectively alleviate adipose inflammation and improve the microenvironment by inhibiting NNMT.

In mouse models of high‑fat diet‑induced obesity, it treatment significantly reduced mRNA and protein expression of TNF‑α, IL‑6, and other inflammatory factors in adipose tissue and decreased macrophage infiltration - a hallmark of adipose inflammation. By increasing NAD⁺ levels and activating the SIRT1 pathway, NNMTi inhibits the activation of inflammatory signaling pathways (such as the NF‑κB pathway), thereby reducing macrophage infiltration and inflammatory factor release. In addition, NNMTi promotes the secretion of anti‑inflammatory lipids (such as PAHSA) by adipocytes, further relieving adipose inflammation and improving metabolic function. These findings indicate that the product not only reduces fat accumulation but also breaks the vicious cycle between obesity and inflammation by regulating adipose tissue inflammation, providing new strategies for research on obesity‑related complications.

Non‑alcoholic fatty liver disease is another major obesity‑related complication, marked by excessive hepatic fat accumulation, which can progress to cirrhosis and liver cancer in severe cases. A major source of hepatic fat is fat mobilization from adipose tissue. In obesity, abnormal adipose metabolism transports large amounts of free fatty acids to the liver, increasing hepatic fat synthesis, decreasing fat breakdown, and ultimately causing hepatic steatosis.

Studies show that NNMT is highly expressed in the liver of obese individuals. Its enhanced activity promotes hepatic lipogenesis, inhibits lipolysis, aggravates liver inflammation, and accelerates NAFLD progression. 5‑Amino‑1MQ Peptide effectively improves hepatic lipid metabolism and reduces liver fat accumulation and inflammation by inhibiting NNMT. In diet‑induced obese mice, NNMTi treatment significantly reduced liver weight, liver volume, and hepatic triglyceride levels, alleviated hepatic steatosis and inflammatory infiltration, downregulated inflammatory factors (such as TNF‑α and IL‑6) and lipogenic genes (such as FAS), and upregulated lipolytic genes (such as ATGL) in the liver.

A large number of in vivo animal experiments have confirmed that it exerts significant weight‑loss and fat‑reducing effects with favorable safety profiles.In a mouse model of high‑fat diet‑induced obesity, administration of 20 mg/kg NNMTi daily for 11 days resulted in a significant reduction in body weight. Compared with the control group, the treated mice showed a 35% decrease in white adipose tissue mass and markedly reduced adipocyte size.

Meanwhile, plasma cholesterol levels were reduced by 30%, and the blood lipid profile recovered to nearly normal levels comparable to lean mice.Another 28‑day experiment demonstrated that 5‑Amino‑1MQ Peptide treatment dose‑dependently suppressed body weight gain and fat accumulation in obese mice, improved insulin sensitivity and hepatic lipid metabolism, without obvious side effects-no abnormalities were observed in food intake, physical activity, or liver and kidney function parameters.

Furthermore, the weight‑loss effect of the product was shown to be sustainable, with no significant body weight rebound in the short term after drug withdrawal, a feature superior to traditional anti‑obesity medications. Meanwhile, NNMTi preserves lean body mass: it reduces fat accumulation without causing muscle loss, which is crucial for maintaining basal metabolism and preventing weight regain after dieting.These in vivo findings fully validate the efficacy and safety of NNMTi in obesity intervention, laying a solid foundation for its subsequent clinical research and drug development.